Tvardi Therapeutics TVRD Institutional Ownership

Updated Oct 5, 2026

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) was reported as a holding by 59 institutional investors in 13F filings for the quarter ended June 30, 2026.

• Together they owned 23.75% of the outstanding stock in Q2 2026, down from 28.82% a quarter earlier.
• Total shares held in TVRD fell 17.59% from Q1 2026; the number of holders rose 22.92% from Q2 2025.
• Of these 59 holders, 22 added to their positions, 23 reduced their stakes and 14 left their positions unchanged.
• The aggregate institutional position in Tvardi Therapeutics was 2.23Mn shares at the end of Q2 2026, down 475.56K from the prior quarter and up 309.52K from a year earlier.
• Slate Path Capital LP held the largest position in TVRD at 704.12K shares as of June 30, 2026, or 7.51% of shares outstanding.
• The largest position increases in TVRD for Q2 2026 were by UBS Group AG (+60.68K shares), Russell Investments Group, Ltd. (+19.92K shares), Morgan Stanley (+4.95K shares), Pnc Financial Services Group, Inc. (+2.79K shares) and Arax Advisory Partners (+2.67K shares).
• The largest position reductions in TVRD for Q2 2026 were by BlackRock, Inc. (-292.6K shares), Geode Capital Management, LLC (-91.99K shares), State Street Corp (-63.33K shares), Northern Trust Corp (-27.25K shares) and AQR Capital Management LLC (-15.1K shares).
• Business Quant data shows the 10 biggest positions in Tvardi Therapeutics as of Q2 2026 were held by Slate Path Capital LP (704.12K shares), Vanguard Capital Management LLC (344.38K shares), American Financial Group Inc (223.66K shares), UBS Group AG (111.13K shares), Silvercrest Asset Management Group LLC (101.03K shares), BlackRock, Inc. (95.48K shares), Renaissance Technologies LLC (91.41K shares), Geode Capital Management, LLC (90.35K shares), Morgan Stanley (77.84K shares) and Duncan Williams Asset Management, LLC (63.24K shares).